{"entity":{"id":"nct05475678","kind":"trial","name":"Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer","aka":[],"tldr":"A phase 2 trial in triple-negative breast cancer, run by Zhenzhen Liu, now recruiting.","summary":"Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer is a phase 2, randomised interventional study registered as NCT05475678 by Zhenzhen Liu, with a registry enrolment figure of 369 participants, started 2022-12-20 and due to reach its primary completion in 2025-05-31. Interventions recorded: （Carrelizumab + TCb） regimen; TCb regimen. Conditions listed: Breast Cancer; Triple Negative Breast Cancer; Camrelizumab. Triple-negative eligibility wording from the registry: \"Pathologically proven triple negative breast cancer:\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05475678","url":"https://clinicaltrials.gov/study/NCT05475678"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05475678","phase":"2","setting":"A Randomized, Open Label, Parallel Controlled, Multicenter Phase II Clinical Study of Carelizumab Combined With TCb (Docetaxel+Carboplatin) Versus TCb Neoadjuvant Therapy for Triple Negative Breast Cancer","sponsor":"Zhenzhen Liu","enrolled":369,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05475678/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}